Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...

In a new study, Ozempic - a drug sold to help with obesity and diabetes - is attributed to helping this disease.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...